NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
27.85
-0.37 (-1.31%)
The current stock price of CGON is 27.85 USD. In the past month the price decreased by -9.43%. In the past year, price decreased by -36.14%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 61 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
CG ONCOLOGY INC
400 Spectrum Center Drive, Suite 2040
Irvine CALIFORNIA US
Employees: 61
Company Website: https://www.cgoncology.com/
Phone: 19492886298
The current stock price of CGON is 27.85 USD. The price decreased by -1.31% in the last trading session.
The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.
CGON stock is listed on the Nasdaq exchange.
14 analysts have analysed CGON and the average price target is 69.8 USD. This implies a price increase of 150.62% is expected in the next year compared to the current price of 27.85. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CG ONCOLOGY INC (CGON) has a market capitalization of 2.08B USD. This makes CGON a Mid Cap stock.
CG ONCOLOGY INC (CGON) currently has 61 employees.
CG ONCOLOGY INC (CGON) has a support level at 27.84 and a resistance level at 28.07. Check the full technical report for a detailed analysis of CGON support and resistance levels.
The Revenue of CG ONCOLOGY INC (CGON) is expected to grow by 412.82% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CGON does not pay a dividend.
CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.31).
The outstanding short interest for CG ONCOLOGY INC (CGON) is 10.09% of its float. Check the ownership tab for more information on the CGON short interest.
ChartMill assigns a fundamental rating of 4 / 10 to CGON. CGON has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -5.31. The EPS decreased by -54.78% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.17% | ||
ROE | -14.59% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to CGON. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 1.8% and a revenue growth 412.82% for CGON